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Abstract: Background: Epidemiological studies observing inconsistent associations of telomere
length (TL) with ischemic stroke (IS) are susceptible to bias according to reverse causation and
residual confounding. We aimed to assess the causal association between TL, IS, and the subtypes
of IS, including large artery stroke (LAS), small vessel stroke (SVS), and cardioembolic stroke
(CES) by performing a series of two-sample Mendelian randomization (MR) approaches. Methods:
Seven single nucleotide polymorphisms (SNPs) were involved as candidate instrumental variables
(IVs), summarized from a genome-wide meta-analysis including 37,684 participants of European
descent. We analyzed the largest ever genome-wide association studies of stroke in Europe from the
MEGASTROKE collaboration with 40,585 stroke cases and 406,111 controls. The weighted median
(WM), the penalized weighted median (PWM), the inverse variance weighted (IVW), the penalized
inverse variance weighted (PIVW), the robust inverse variance weighted (RIVW), and the Mendelian
randomization-Egger (MR-Egger) methods were conducted for the MR analysis to estimate a causal
effect and detect the directional pleiotropy. Results: No significant association between genetically
determined TL with overall IS, LAS, or CES were found (all p > 0.05). SVS was associated with TL
by the RIVW method (odds ratio (OR) = 0.72, 95% confidence interval (CI): 0.54–0.97, p = 0.028),
after excluding rs9420907, rs10936599, and rs2736100. Conclusions: By a series of causal inference
approaches using SNPs as IVs, no strong evidence to support the causal effect of shorter TL on IS and
its subtypes were found.
Keywords: Mendelian randomization study; single nucleotide polymorphisms; instrumental variable;
ischemic stroke; telomere length
1. Introduction
According to the World Health Organization, in 2016 stroke was the second leading cause of
death worldwide and a major contributor to disability, with ischemic stroke (IS) blocked blood vessels
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accounting for 87% of all stroke cases, compared to hemorrhagic stroke (HS) bleeding blood vessels in
the brain accounting for 13% [1]. IS is a complex syndrome triggered by embolisms from the heart,
artery-to-artery embolism, and in situ small vessel disease [2], finally leading to severely reduced
blood flow and brain damage. The major etiological subtypes of IS are large artery stroke (LAS),
cardioembolic stroke (CES), and small vessel stroke (SVS) [3]. The pathogenesis of IS is complicated
and involves many different predisposing factors. With the ongoing demographic changes of aging of
the population and health transitions, IS remains a major global health problem and its significance
is predicted to increase in the future. While modifiable risk factors such as hypertension, obesity,
smoking, physical inactivity, inflammatory disorders, and infections are believed to contribute to the
disease risk, interventions have primarily focused on preventing the environmental interactions with
genetic factors.
Telomeres are genetic DNA-protein complexes that include TTAGGG nucleotide repeats at the
end of eukaryotic chromosomes, interacting with the environment to maintain the integrity and
stability of the genome during cellular replication. Shorter telomeres are shown to be associated with
increased all-cause mortality risk in the general population [4,5], resulting from cellular dysfunction,
senescence and death [6,7]. Telomere dysfunction, a biomarker of cellular aging, may contribute to
vascular aging [8]. Vascular aging is characterized by a gradual change of structure and function
resulting in increased arterial stiffening. Oxidative stress and vascular inflammation are the principal
drivers in endothelial dysfunction and atherosclerosis. They are also supposed to cause accelerated
telomere attrition and subsequent premature cellular senescence in endothelial cells, vascular smooth
muscle cells, and blood leukocytes [9]. In patients with an acute coronary syndrome, telomere
loss has been reported to be associated with the risk of highly unstable atherosclerotic plaques and
increased pro-inflammatory activity [9]. Pulse wave velocity, which increases with arterial stiffness,
is the finite speed at which a heart contraction generating a pressure wave propagates through the
circulatory system [10]. A previous study found differential relationships between aortic pulse wave
velocity and telomere length (TL) in different age subjects [11]. In younger subjects (aged < 30 years),
TL was significantly shorter among people with high aortic pulse wave velocity. By contrast, in those
aged > 50 years there was a positive association with longer TL and high aortic pulse wave velocity.
This indicates that the links between cellular senescence and vascular aging reflect complex regulatory
mechanisms acting over the life-course.
The role of TL on vascular aging suggests that TL may potentially impact the onset of IS subtypes
through atherosclerosis. In terms of LAS, it occurs when thrombosis or embolism blocks blood flow of
brain vascular with atherosclerotic plaque and decreases the blood supply to that part of the brain [12].
SVSs are small infarcts resulting from the occlusion of penetrating branches of cerebral arteries that
provide blood to the brain’s deep structures [13]. SVS is characterized pathologically by lipohyalinosis,
arteriolosclerosis, and atherosclerosis (microatheroma). Endothelial dysfunction may be the major
pathogenic mechanism for SVS, as to CES, for which risk factors include atrial fibrillation and aortic
arch atheroma. Aging and multiple vascular risk factors result in an abnormal atrial substrate or atrial
cardiopathy via a complex thrombo-genesis pathway, further increasing the risk of CES [14]. A large
and rapidly expanding quantity of literature has reported the associations between TL and IS [15,16].
These observational studies, however, have consistently shown a controversial unexplainable inverse
relationship between TL and IS [17,18]. To date, the causal effect between TL and IS remains unknown;
thus, an urgent need to investigate the causal relationship for improving the strategies of stroke
prevention and management is required.
Mendelian randomization (MR) is fast becoming a popular method to investigate the causality
from routinely conducted observational studies using genetic variations as a natural experiment
and instrumental variables (IVs) to avoid the conventional bias of reverse causation and residual
confounding [19]. A recent MR study [20] showed that shorter TL was marginally associated with
decreased risk of stroke, which is inconsistent with previous studies. Furthermore, the role of shortened
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telomeres on coronary heart disease may act via fasting insulin level as a mediator based on MR
analysis [21]. Type 2 diabetes may be causally associated with LAS [22].
In the present study, we performed a series of multiple-instrument two-sample MR analyses with
summarized data from published genome-wide association studies (GWASs) to decipher the causal
role of TL in IS subtypes, and to provide insight into potential mechanisms.
2. Materials and Methods
2.1. Data Source and Single Nucleotide Polymorphism(SNP)Selection
From a GWAS of TL in the ENGAGE Telomere Consortium [23], based on 37,684 individuals of
European ancestry, we selected seven SNPs in seven loci that were associated with TL at a genome-wide
significance threshold (p < 5 × 10−8). The association estimate for the “short” allele (in terms of per
standard deviation decrease in TL per allele), standard error, and p-value for each SNP were obtained.
The proportion of variance in average TL explained by individual SNPs ranged from 0.08% to 0.36%.
Data of seven TL-related SNPs with IS and its subtypes were retrieved as summary statistics from
438,847 European-descent individuals (40,585 cases; 406,111 controls) included in the MEGASTROKE
collaboration [24]. The Trial of ORG 10172 in Acute Stroke Treatment criteria was used for IS subtyping,
identifying 4373 LAS cases, 7193 CES cases, and 5386 SVS cases. Brain imaging was used to reconfirm
that all cases were IS.
All participants provided written informed consent in all these corresponding original studies.
Each study included in the stroke consortia was approved by the local institutional review board and
ethics committee.
2.2. Statistical Analysis
MR is a type of instrumental variable analysis using genetic variants, such as SNPs, as proxies for
risk factors of interests. MR assumes that SNPs are randomly distributed in the general population
according to Mendel’s laws of inheritance (segregation, independent assortment), mimicking a
randomization process, and that SNPs always precede the onset of disease, and thus could eliminate
reverse causality. Three important assumptions need to be proved to ensure a valid IV within the MR
analysis process [25]: (1) the genetic variants used as IVs are truly predictive of TL; (2) the genetic
variants are not associated with measured and unmeasured confounders that influence both TL and
stroke; and (3) the genetic variants affect stroke through their effects on TL only and not through any
alternative causal pathways.
The standard application of MR is a one-sample MR, which is performed within one population
set containing complete data on the SNPs, exposure, and outcome for all participants [26]. Due to the
rareness of comprehensive data in one single cohort, a two-sample MR is developed to allow analysis
conducted in two separate samples—one for the exposure of interest and the other for the outcome [25].
In this study, we conducted six two-sample MR methods using “MendelianRandomization” R
package [27], including the weighted median (WM), the penalized weighted median (PWM),
the inverse variance weighted (IVW), the penalized inverse variance weighted (PIVW), the robust
inverse variance weighted (RIVW), and the Mendelian randomization-Egger (MR-Egger) methods [28].
According to the advantages of each MR approach, these six methods can complement each other
to provide a more reliable causal effect for our study. The inverse variance weighted methods are
conventionally used in two-sample MR analysis. The MR-Egger methods are able to provide estimates
of the casual effect, as well as to assess the directional pleiotropy under the weaker assumption, i.e.,
the “Instrument Strength Independent of Direct Effect (InSIDE)” assumption. The median-based
methods could give consistent estimates when 50% or more of the genetic variants are valid IVs, which
may be more appropriate than the MR-Egger methods in the existence of outlier genetic variants.
The weighted methods provide more precise causal estimates based on more weight to the analysis.
The penalized methods contribute to avoid the influence of pleiotropic effect in casual inference by
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omitting part of the genetic variants from the analysis. The robust methods make consistent estimates
of causal effect under weaker assumptions than those of a conventional MR analysis.
In the current study, we primarily estimated the effect of TL on IS and its subtypes using the
conventional IVW method [29], which is an appropriate approach using summarized data from GWAS
(individual-level data were not available). First, we conducted inverse variance weighting average of
SNP-specific association with fixed effects in all types of IS other than CES. This analysis gives biased
estimates if some of the instruments are invalid in the assumptions for causal inference based on the
MR analysis [30]. Then, we addressed the first assumption (a true association between SNPs and TL)
by selecting SNPs that strongly predicted TL. Genetic variants as proxies for TL were likely to satisfy
the second assumption (no confounders existing).
To assess the potential violation of the third assumption, the MR-Egger method was performed
to confirm no directional pleiotropy if there is no intercept term. Scatter plots were then created to
investigate the potential pleiotropy visually by presenting the associations between each SNP and the
IS risk against associations with TL. Sensitivity analyses were performed to evaluate the robustness
of results using WM, PWM, PIVW, RIVW, and MR-Egger methods. Finally, a power analysis using
a web-based application was conducted (http://cnsgenomics.com/shiny/mRnd/) [31] to estimate
the minimum detectable magnitude of association for IS, in terms of odds ratio (OR) per standard
deviation of TL. The estimation of the detectable OR was obtained after specifying 80% power with
5% significance and by assuming that the variance in TL explained by the seven SNPs was 0.01 or
0.02, respectively.
All statistical tests were two-sided, and the evidence of association was declared at a pre-specified
p-value below 0.05. The analyses were conducted using R version 3.3.3 and Stata/MP13.1 (Stata/MP,
Texas, USA).
3. Results
3.1. Association of Genetic Variables with TL
Summarized data extracted from reported lectures are given in Table 1. We estimated the
associations between each TL-related SNP and risk for IS and the subtypes, shown as forest plots in
Figure 1. Two of seven SNPs used as IVs in the MR analyses demonstrated that TL was associated with
CES (p = 0.023 for rs2736100 and p = 0.003 for rs11125529), however, the association had a different
direction. Genetic prediction of shorter TL using SNP rs9420907 as a proxy was associated with SVS
with statistical significance (p = 0.029).
Table 1. Summarized data for the genetic variants associated with telomere length.
SNP Chr. Locus ‘Short’Allele
‘Other’
Allele
Beta
Estimate SE Discovery p
rs10936599 3 TERC T C −0.097 0.008 2.5 × 10−31
rs2736100 5 TERT A C −0.078 0.009 4.4 × 10−9
rs7675998 4 NAF1 A G −0.074 0.009 4.3 × 10−16
rs9420907 10 OBFC1 A C −0.069 0.010 6.9 × 10−11
rs8105767 19 ZNF208 A G −0.048 0.008 1.1 × 10−9
rs755017 20 RTEL1 A G −0.062 0.011 6.7 × 10−9
rs11125529 2 ACYP2 C A −0.056 0.010 4.5 × 10−8
Chr.: chromosome; SE: standard error; SNP: single nucleotide polymorphism.
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Figure 1. Forest plots and scatter plots of associations between telomere length (TL)-related single
nucleotide polymorphisms (SNPs) and risk for all types and subtypes of ischemic stroke (IS).
All ischemic stroke: (A1,A2); large artery stroke: (B1,B2); cardioembolic stroke: (C1,C2); small
vessel stroke: (D1,D2). Forest plots (A1,B1,C1,D1) show the odds ratio (OR) with a horizontal line
representing 95% confidence intervals (CIs) for the ‘short telomere’-associated SNP allele for stroke
risk. Scatter plots (A2,B2,C2,D2) show the per-allele association with stroke risk plotted against the
per-allele association with one standard deviation of TL (with vertical and horizontal black lines
showing the 95% CI for each SNP). The slope of the red solid line (with dotted lines showing the 95%
CI) in the scatter plots corresponds to the Mendelian randomization (MR) estimate.
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3.2. Association of TL with IS
The MR estimates of TL on IS using conventional MR analysis are presented in Table 2. The IVW
estimate using all seven SNPs showed no clear association between shorter TL and stroke (all ischemic
stroke (AIS), OR = 0.96, 95% confidence interval (CI): 0.85–1.09; LAS, OR = 0.90, 95% CI: 0.66–1.24; CES,
OR = 0.82, 95% CI: 0.52–1.3VS, OR = 1.06, 95% CI: 0.76–1.48).
Table 2. Odds ratios for the association between TL and IS and its subtypes using different
methodological approaches and exclusions for pleiotropic SNPs.
Ischemic Stroke
IVW RIVW MR-Egger
OR (95% CI) p OR (95% CI) p OR (95% CI) p Intercept (p)
AIS 0.96 (0.85, 1.09) 0.535 0.96 (0.87, 1.07) 0.452 1.32 (0.73, 2.37) 0.354 −0.02 (0.277)
LAS
ALL SNPs 0.90 (0.66, 1.24) 0.530 0.90 (0.62, 1.30) 0.569 3.45 (0.79, 15.07) 0.100 −0.10 (0.054)
6 SNPs 1 0.79 (0.54, 1.15) 0.210 0.84 (0.29, 2.39) 0.741 2.94 (0.34, 25.33) 0.327 −0.09 (0.224)
CES
ALL SNPs 0.82 (0.52, 1.32) 0.417 0.91 (0.56, 1.46) 0.683 1.56 (0.17, 13.96) 0.691 −0.04 (0.080)
5 SNPs 2 0.76 (0.39, 1.46) 0.404 0.98 (0.53, 1.80) 0.941
9.44 (0.55,
163.04) 0.123 −0.15 (0.112)
SVS
ALL SNPs 1.06 (0.76, 1.48) 0.722 1.03 (0.72, 1.48) 0.867 2.59 (0.59, 11.38) 0.208 −0.07 (0.054)
4 SNPs 3 0.72 (0.45, 1.16) 0.176 0.72 (0.54, 0.97) 0.028 1.13 (0.07, 18.38) 0.932 −0.03 (0.747)
IVW: the inverse variance weighted method; RIVW: the robust inverse variance weighted method; MR-Egger: the
Mendelian randomization-Egger method; OR: odds ratio; CI: confidence interval; AIS: all ischemic stroke; LAS:
large artery stroke; CES: cardioembolic stroke; SVS: small vessel stroke. 1: analysis excluding rs9420907; 2: analysis
excluding rs2736100 and rs9420907; 3: analysis excluding rs9420907, rs10936599, and rs2736100.
The associations of TL with all stroke subtypes were consistent in the sensitivity analysis that used
the WM, PWM, PIVW, and RIVW methods but not in the MR-Egger method (Figure S1). The MR-Egger
intercept test suggested a potential directional pleiotropy (p = 0.054 for LAS, p = 0.080 for CES, p = 0.054
for CES, using all seven SNPs), which was also reflected in the scatter plots (Figure 1). After excluding
rs9420907, rs10936599, and rs2736100, shorter TL was associated with SVS (OR = 0.72, 95% CI: 0.54–0.97,
p = 0.028) using the PIVW approach. However, we observed no such association for the other IS
subtypes after excluding rs9420907 for LAS, and excluding rs2736100 and rs9420907 for CES.
The statistical power analysis of this current MR study is given in Table S1. Based on the sample
size of 438,847, our MR analysis would need to have over 80% power at an alpha rate of 5% to detect
a statistically significant causal effect of a relative 14.5% decrease in overall IS risk per one standard
deviation of TL; the corresponding estimates were 51.0%, 32.8%, and 33.5% relative reductions for
LAS, CES, and SVS (i.e., ORs of 0.490, 0.672, and 0.665, respectively).
4. Discussion
In the present study, we investigated the potential causal role of TL in the development of IS and
its subtypes by performing a series of complementary MR methods. With genetic variants as proxies
for TL, our study only showed a suggestive association between shorter TL and SVS risk based on
PIVW after the exclusion of potential invalid SNPs. The results provided no strong evidence for a
causal role of TL in overall IS and any other subtypes, including LAS, SVS, and CES.
The MR-Egger estimate was discordant with conventional results on IS and its subtypes, although
the potential pleiotropic SNPs were excluded. It is possible for the MR-Egger estimate to be biased due
to the violations of the InSIDE assumption [32]. The WM method, as an alternative pleiotropy-robust
estimation strategy, provides a valid estimate if at least 50% of selected genetic variants are valid
IVs [33]. Further, the WM method gives a consistent estimate with other penalized and robust
approaches when a causal effect of shorter TL on SVS is explored.
Despite previous cross-sectional studies showing an association between shorter TL and IS risk,
such a relationship has not been firmly endorsed by evidence from prospective studies [33–35], which
is consistent with our results regarding the role of TL in overall IS. The meta-analysis consisting of
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six prospective studies identified no evidence of an association between TL and IS risk [34]. Similar
results were also found in a pool-analysis [35]. In contrast to a meta-analysis that aggregated data
from 11 cohort studies, the association between TL and stroke was found to be significant in a pooled
analysis, but was not found in subgroup analysis, in either the prospective or retrospective study
subgroups [36].
Due to the different pathologies in IS subtypes and the different scales of effect sizes in different
original studies, results of the meta-analysis may be less reliable. Two MR studies were performed
to examine the association between TL and stroke [20,37]. The first MR study showed that shorter
telomere is a protective factor with marginally decreased risk of stroke based on individual-level data
and small sample size of 6426 cases [20]. The second study showed the lack of a clear association of TL
on the risk of all IS subtypes [37]. These results are comparable with our finding in all subtypes except
SVS, whereas the estimates in our study were based on a larger sample size of 40,585 cases.
There were several published studies on TL and IS subtypes [11,15,38]. A prospective study found
that shorter TL is associated with LAS, but is not statistically associated with SVS [15]. The association
between shorter TL and increased CES risk was also reported in a retrospective study [38]. In contrast,
we observed a potential association between TL shortening and decreased risk for SVS, and a null
relationship of TL with LAS and CES. Learning that the complex association between aortic pulse wave
velocity (as a biomarker of arterial stiffness) and TL changes with age [11], the non-linear relationship
between TL and IS subtypes may be limited to detect their association. Further, the null association
between TL and CES was essentially unchanged, despite the inclusion of rs7675998, which showed
an association with increased risk of CES [38]. Due to the complex reason of cardiogenic thrombus,
the role of TL on CES should be analyzed by stratified analysis on locations of thrombus to reduce
such biases. In addition, it was reported that lower general cognitive ability level was associated with
shorter TL [39], and shorter TL was causally related to a higher risk of suffering from Alzheimer’s
disease [40]. The findings of previous studies imply that our result pertaining to TL with SVS may
involve the same pathogenesis of cerebral small vessel disease for SVS [41]. Therefore, the role of TL
on SVS warrants further investigation.
Our MR study has several strengths. First, our study investigated the largest dataset included in
the MEGASTROKE collaboration, with a total of 438,847 European-descent individuals (40,585 cases
and 406,111 controls), which minimizes the influence of population stratification. Second, as a result of
the MR design, we conducted six complementary MR methods to prevent the reverse causation bias
and to reduce potential confounding. Third, the IVs used in our study were independent SNPs, which
could maximally reduce the interference of linkage disequilibrium.
Potential limitations in our study include the third stringent assumption in MR analysis
needing to be proved. Additionally, potential nonlinearity roles of TL on IS were unable to be
explored as individual-level data were not available [42]. Our power estimation enabled us to detect
low-to-moderate associations based on very large sample sizes, which is limited by a small fraction
of the variation in TL explained by SNPs (1%) [43]. Furthermore, we could not confirm that the
associations between SNPs and TL were consistent across multiple tissues due to a lack of TL-related
GWAS data on specific tissue. However, leukocyte TL could warrant a surrogate marker of TL
in other tissues because the relevance between different tissues in the same individual has been
demonstrated [44]. Finally, we could not assess compensatory mechanisms which attenuate the
estimates and thus lower precision.
5. Conclusions
Using TL-associated SNPs as instrumental variables extracted from the GWAS data consisting
of large European-descent cohorts, our MR analyses do not support a causal effect of shorter TL
(exposures) on IS or its subtypes (outcome variables). Our results suggest that shorter TL may be a
potential causal risk factor for SVS, but there remains a lack of evidence for a causal role of TL for LAS
and CES. Further MR studies using individual-level data based on larger sample sizes are required to
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delineate any potential nonlinearity between TL and IS risk and to identify the effects of TL across
subclasses of IS subtypes.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/2/159/s1,
Figure S1: Sensitivity analysis for the associations of genetically predicted TL with ischemic stroke and its subtypes;
Table S1: Approximate detectable odds ratio (OR) per one standard deviation of telomere length.
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